Peer Review History

Original SubmissionAugust 26, 2020
Decision Letter - Khatijah Lim Abdullah, Editor

PONE-D-20-26810

Normalisation process theory and the implementation of a new glaucoma clinical pathway in hospital eye services: Perspectives of doctors, nurses and optometrists

PLOS ONE

Dear Dr. Read,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 25 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Khatijah Lim Abdullah, DClinP, MSc., BSc

Academic Editor

PLOS ONE

Journal Requirements:

1) Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

2)  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

3) Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

4)  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: A well written paper applying NPT to understanding implementation feasibility for a 4hour-4week glaucoma treatment program. Some minor comments as follows:

Line 179- please clarify what does "independent of the health board" mean.

Line 191- Under clinical observations. Because it is not clear how many researchers were collecting the data it would be helpful to explain what is meant by "52 week-by-week.." means. Is it 52 consecutive weeks? Or 52 field notes? Please state if these field notes are referencing the "wider observational data" in Line 187, are they the same thing?

Line 209 "favourable ethical opinion" sounds odd, is this equivalent to ethical approval?

Line 233 "where data should sit" It is not clear what this phrase means.

Line 259 Staffing - what is the value of about mapping not having a staff to NPT constructs (in this case cognitive participation>initiation, enrolment), rather than just using a more straightforward implementation framework that would mention manpower/ staffing/ champions? This for me seems counter intuitive especially for someone more familiar with other implementation frameworks. Suggest to consider this as the NPT fit is discussed under Discussion>limitations.

Line 315- It is hard to tell who these staff are in terms of having more formal knowledge of glaucoma, perhaps some indicator of why they are considered so should be included after their quotes e.g. OH 301 (<state etc job level of position training>)

Line 397 - This theme is quite relevant as the 4 hour + 4 week schedule clearly illustrates how elasticity and plasticity can be applied to analysing feasibility. However, I wonder if the CMGC is really just about these larger parameters which were of course quite easy to predict in terms of how they would affect feasibility. It would be interesting if authors could also illustrate more macro level examples of these concepts to show how smaller instructions in the CMGC were either elastic/ plastic or not.

Line 420- " that the retention rate of patients for all procedures ran at 94.3%" Should clarify if this refers to CMGC and if so across the same period of observation as this study (ie was it a sister/ substudy)?</state>

Reviewer #2: The manuscript met all the guidelines from the introduction, methods, results, discussion and conclusion.

The study used was a non-randomised observational type with an ethnographic approch to the qualitative elements which gave a good picture of the data. The limitations were well dcumented as to the small pool of particiapnts.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Lee Yew Kong

Reviewer #2: Yes: Laly Joseph

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Our cover letter provides more detail on our responses to the wider feedback and criteria from the journal, alongside the review feedback responses outlined below.

Reviewer 1 Line 179- please clarify what does "independent of the health board" mean.

This phrase is indicating that the researchers conducting the fieldwork were employed by a separate institution, e.g. Cardiff University, and were independent from the day-to-day activities of the health board in which they were performing the research. We have changed the phrase to be ‘independent from the clinical team’ and believe this should enhance the clarity for readers.

Reviewer 1 Line 191- Under clinical observations. Because it is not clear how many researchers were collecting the data it would be helpful to explain what is meant by "52 week-by-week." means. Is it 52 consecutive weeks? Or 52 field notes? Please state if these field notes are referencing the "wider observational data" in Line 187, are they the same thing?

We agree that this would benefit from further clarity. As we have established the nature of the field notes in question in the previous two sentences, we have adjusted the wording here to be: “A total of 52 of these observational field notes were taken over the duration of the study covering the majority of research visits”

Reviewer 1 Line 209 "favourable ethical opinion" sounds odd, is this equivalent to ethical approval?

Yes – it is exactly the same but is based on the terminology of the UK-based ethical committees. Given the international readership and audience of PLOS ONE, we have amended this to ‘ethical approval’ for the purposes of this article.

Reviewer 1 Line 233 "where data should sit" It is not clear what this phrase means.

We have adapted this sentence to further enhance clarity. This now reads ‘where data fitted within the developing themes’.

Reviewer 1 Line 259 Staffing - what is the value of about mapping not having a staff to NPT constructs (in this case cognitive participation>initiation, enrolment), rather than just using a more straightforward implementation framework that would mention manpower/ staffing/ champions? This for me seems counter intuitive especially for someone more familiar with other implementation frameworks. Suggest to consider this as the NPT fit is discussed under Discussion>limitations.

We have added some wordings in the Study Limitations section as suggested, including reference to frameworks where implementation issues related to staffing are more clearly established, such as through the processes of knowledge translation approaches and the use of change champions during implementation etc.

Reviewer 1 Line 315- It is hard to tell who these staff are in terms of having more formal knowledge of glaucoma, perhaps some indicator of why they are considered so should be included after their quotes e.g. OH 301 ()

We have provided one or two examples within the text to highlight what is intended by this phrase. There is a risk that by aligning these to specific quotes that we enable identification of participants so believe this to be a preferable solution.

Reviewer 1 Line 397 - This theme is quite relevant as the 4 hour + 4 week schedule clearly illustrates how elasticity and plasticity can be applied to analysing feasibility. However, I wonder if the CMGC is really just about these larger parameters which were of course quite easy to predict in terms of how they would affect feasibility. It would be interesting if authors could also illustrate more macro level examples of these concepts to show how smaller instructions in the CMGC were either elastic/ plastic or not.

We feel that we have offered a thorough discussion of this topic and highlighted several macro level examples within the Discussion section (lines 448-495 and 513-532). Given the other changes we have made above, particularly in relation to ref: 009 in the limitations section, we believe this comment is adequately covered.

Reviewer 1 Line 420- " that the retention rate of patients for all procedures ran at 94.3%" Should clarify if this refers to CMGC and if so across the same period of observation as this study (ie was it a sister/ substudy)?

We have clarified this in-text by confirming that the retention rate was for all CMGC study procedures.

Attachments
Attachment
Submitted filename: Reviewer Responses.docx
Decision Letter - Khatijah Lim Abdullah, Editor

Normalisation process theory and the implementation of a new glaucoma clinical pathway in hospital eye services: Perspectives of doctors, nurses and optometrists

PONE-D-20-26810R1

Dear Dr. Read,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Khatijah Lim Abdullah, DClinP, MSc., BSc

Academic Editor

PLOS ONE

Reviewers' comments:

Comments to the Author

 All comments have been addressed

**********

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

**********

**********

Formally Accepted
Acceptance Letter - Khatijah Lim Abdullah, Editor

PONE-D-20-26810R1

Normalisation process theory and the implementation of a new glaucoma clinical pathway in hospital eye services: Perspectives of doctors, nurses and optometrists

Dear Dr. Read:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Khatijah Lim Abdullah

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .